Skip to main content
Journal cover image

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.

Publication ,  Journal Article
Pollack, CV; Reilly, PA; Bernstein, R; Dubiel, R; Eikelboom, J; Glund, S; Huisman, MV; Hylek, E; Kam, C-W; Kamphuisen, PW; Kreuzer, J; Wang, B ...
Published in: Thromb Haemost
July 2015

Idarucizumab, a Fab fragment directed against dabigatran, produced rapid and complete reversal of the anticoagulation effect of dabigatran in animals and in healthy volunteers. The Study of the REVERSal Effects of Idarucizumab in Patients on Active Dabigatran (RE-VERSE AD™) is a global phase 3 prospective cohort study aimed at investigating idarucizumab in dabigatran-treated patients who present with uncontrollable or life-threatening bleeding, and in those requiring urgent surgery or intervention. We describe the rationale for, and design of the trial (clinicaltrials.gov NCT02104947).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Thromb Haemost

DOI

EISSN

2567-689X

Publication Date

July 2015

Volume

114

Issue

1

Start / End Page

198 / 205

Location

Germany

Related Subject Headings

  • Treatment Outcome
  • Research Design
  • Humans
  • Hemorrhage
  • Dabigatran
  • Coagulants
  • Clinical Protocols
  • Cardiovascular System & Hematology
  • Blood Loss, Surgical
  • Blood Coagulation Tests
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pollack, C. V., Reilly, P. A., Bernstein, R., Dubiel, R., Eikelboom, J., Glund, S., … Weitz, J. I. (2015). Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost, 114(1), 198–205. https://doi.org/10.1160/TH15-03-0192
Pollack, Charles V., Paul A. Reilly, Richard Bernstein, Robert Dubiel, John Eikelboom, Stephan Glund, Menno V. Huisman, et al. “Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.Thromb Haemost 114, no. 1 (July 2015): 198–205. https://doi.org/10.1160/TH15-03-0192.
Pollack CV, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015 Jul;114(1):198–205.
Pollack, Charles V., et al. “Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.Thromb Haemost, vol. 114, no. 1, July 2015, pp. 198–205. Pubmed, doi:10.1160/TH15-03-0192.
Pollack CV, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, Huisman MV, Hylek E, Kam C-W, Kamphuisen PW, Kreuzer J, Levy JH, Sellke F, Stangier J, Steiner T, Wang B, Weitz JI. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015 Jul;114(1):198–205.
Journal cover image

Published In

Thromb Haemost

DOI

EISSN

2567-689X

Publication Date

July 2015

Volume

114

Issue

1

Start / End Page

198 / 205

Location

Germany

Related Subject Headings

  • Treatment Outcome
  • Research Design
  • Humans
  • Hemorrhage
  • Dabigatran
  • Coagulants
  • Clinical Protocols
  • Cardiovascular System & Hematology
  • Blood Loss, Surgical
  • Blood Coagulation Tests